JP7346420B2 - 芳香族誘導体、その調製方法、およびその医学的適用 - Google Patents

芳香族誘導体、その調製方法、およびその医学的適用 Download PDF

Info

Publication number
JP7346420B2
JP7346420B2 JP2020533340A JP2020533340A JP7346420B2 JP 7346420 B2 JP7346420 B2 JP 7346420B2 JP 2020533340 A JP2020533340 A JP 2020533340A JP 2020533340 A JP2020533340 A JP 2020533340A JP 7346420 B2 JP7346420 B2 JP 7346420B2
Authority
JP
Japan
Prior art keywords
group
alkyl
independently
pharmaceutically acceptable
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020533340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532581A5 (enExample
JP2020532581A (ja
Inventor
邵▲寧▼
王丁
袁宏斌
フランク カイザー，
Original Assignee
バイオアーディス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアーディス エルエルシー filed Critical バイオアーディス エルエルシー
Publication of JP2020532581A publication Critical patent/JP2020532581A/ja
Publication of JP2020532581A5 publication Critical patent/JP2020532581A5/ja
Priority to JP2023144389A priority Critical patent/JP2023158113A/ja
Application granted granted Critical
Publication of JP7346420B2 publication Critical patent/JP7346420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020533340A 2017-09-05 2018-09-04 芳香族誘導体、その調製方法、およびその医学的適用 Active JP7346420B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023144389A JP2023158113A (ja) 2017-09-05 2023-09-06 芳香族誘導体、その調製方法、およびその医学的適用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710791233 2017-09-05
CN201710791233.1 2017-09-05
PCT/CN2018/104007 WO2019047826A1 (zh) 2017-09-05 2018-09-04 芳香类衍生物、其制备方法及其在医药上的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023144389A Division JP2023158113A (ja) 2017-09-05 2023-09-06 芳香族誘導体、その調製方法、およびその医学的適用

Publications (3)

Publication Number Publication Date
JP2020532581A JP2020532581A (ja) 2020-11-12
JP2020532581A5 JP2020532581A5 (enExample) 2021-10-14
JP7346420B2 true JP7346420B2 (ja) 2023-09-19

Family

ID=65634601

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020533340A Active JP7346420B2 (ja) 2017-09-05 2018-09-04 芳香族誘導体、その調製方法、およびその医学的適用
JP2023144389A Pending JP2023158113A (ja) 2017-09-05 2023-09-06 芳香族誘導体、その調製方法、およびその医学的適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023144389A Pending JP2023158113A (ja) 2017-09-05 2023-09-06 芳香族誘導体、その調製方法、およびその医学的適用

Country Status (10)

Country Link
US (1) US11279697B2 (enExample)
EP (1) EP3680236A4 (enExample)
JP (2) JP7346420B2 (enExample)
KR (1) KR102677016B1 (enExample)
CN (1) CN110997637B (enExample)
CA (1) CA3074885A1 (enExample)
PH (1) PH12020500436A1 (enExample)
SG (1) SG11202001979PA (enExample)
TW (1) TWI817955B (enExample)
WO (1) WO2019047826A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
WO2021060307A1 (ja) * 2019-09-25 2021-04-01 富士フイルム株式会社 イミダゾピリジン化合物またはその塩および医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057963A1 (en) 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
CN105906630A (zh) 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
US8802697B2 (en) 2012-07-11 2014-08-12 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
JP6655559B2 (ja) 2014-06-24 2020-02-26 コベストロ、ドイチュラント、アクチエンゲゼルシャフトＣｏｖｅｓｔｒｏ Ｄｅｕｔｓｃｈｌａｎｄ Ａｇ ジフェニルメタン系ジアミンおよびポリアミンの製造方法
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) * 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057963A1 (en) 2013-10-18 2015-04-23 Eisai R&D Management Co., Ltd. Fgfr4 inhibitors
CN105906630A (zh) 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Also Published As

Publication number Publication date
KR20200083448A (ko) 2020-07-08
TW201912631A (zh) 2019-04-01
US11279697B2 (en) 2022-03-22
KR102677016B1 (ko) 2024-06-19
PH12020500436A1 (en) 2021-02-08
CN110997637B (zh) 2022-09-27
WO2019047826A1 (zh) 2019-03-14
EP3680236A1 (en) 2020-07-15
JP2020532581A (ja) 2020-11-12
SG11202001979PA (en) 2020-04-29
TWI817955B (zh) 2023-10-11
CA3074885A1 (en) 2019-03-14
CN110997637A (zh) 2020-04-10
EP3680236A4 (en) 2021-04-21
US20200262827A1 (en) 2020-08-20
JP2023158113A (ja) 2023-10-26

Similar Documents

Publication Publication Date Title
CN112601750B (zh) Ptpn11（shp2）抑制剂
JP6819585B2 (ja) Ｂｒｋ阻害化合物
JP5808408B2 (ja) フタラジノンケトン誘導体、その製造法および医薬用途
JP6534675B2 (ja) ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
CN102131807B (zh) 吡唑并吡啶激酶抑制剂
CN115490709A (zh) 一种krasg12d抑制剂及其在医药上的应用
JP6907351B2 (ja) 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
KR20190014505A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
BR112012002854B1 (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica e uso dos mesmos
TW201629037A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
CN105934248A (zh) 取代的吡咯并吡啶和吡咯并吡嗪用于治疗癌症或炎性疾病
JP2018532698A (ja) カルボキシ置換（ヘテロ）芳香環誘導体並びにその調製方法及び使用
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2023158113A (ja) 芳香族誘導体、その調製方法、およびその医学的適用
EP4606801A1 (en) Fused heterocyclic compound and use thereof
WO2015134171A1 (en) Heteroarylamide inhibitors of tbk1
WO2018072707A1 (zh) 芳香族醚类衍生物、其制备方法及其在医药上的应用
WO2018121774A1 (zh) 一种选择性抑制激酶化合物及其用途
WO2022089389A1 (zh) 杂环化合物及其制备方法、药物组合物和应用
CN109535132B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN115340561A (zh) Shp2磷酸酶稠环类抑制剂的制备及其应用
CN112625025B (zh) 吡啶基取代的喹啉类衍生物及其制备方法和用途
HK40020552B (en) Aromatic derivative, preparation method for same, and medical applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210902

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230807

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230906

R150 Certificate of patent or registration of utility model

Ref document number: 7346420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150